JP2024521408A5 - - Google Patents
Info
- Publication number
- JP2024521408A5 JP2024521408A5 JP2023575753A JP2023575753A JP2024521408A5 JP 2024521408 A5 JP2024521408 A5 JP 2024521408A5 JP 2023575753 A JP2023575753 A JP 2023575753A JP 2023575753 A JP2023575753 A JP 2023575753A JP 2024521408 A5 JP2024521408 A5 JP 2024521408A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- amino acid
- acid sequence
- polypeptide chain
- polypeptide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163208514P | 2021-06-09 | 2021-06-09 | |
| US63/208,514 | 2021-06-09 | ||
| PCT/EP2022/065514 WO2022258673A1 (en) | 2021-06-09 | 2022-06-08 | Multispecific antibodies binding to cd20, nkp46, cd16 and conjugated to il-2 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024521408A JP2024521408A (ja) | 2024-05-31 |
| JP2024521408A5 true JP2024521408A5 (https=) | 2025-06-16 |
Family
ID=82214258
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023575753A Pending JP2024521408A (ja) | 2021-06-09 | 2022-06-08 | Ｃｄ２０、ｎｋｐ４６、ｃｄ１６に結合し、かつｉｌ－２にコンジュゲートされた多特異性抗体 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20250002601A1 (https=) |
| EP (1) | EP4351733A1 (https=) |
| JP (1) | JP2024521408A (https=) |
| KR (1) | KR20240019786A (https=) |
| CN (1) | CN117529504A (https=) |
| AU (1) | AU2022288574A1 (https=) |
| BR (1) | BR112023025476A2 (https=) |
| CA (1) | CA3227227A1 (https=) |
| IL (1) | IL308531A (https=) |
| MX (1) | MX2023014645A (https=) |
| WO (1) | WO2022258673A1 (https=) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111201030B (zh) | 2017-07-25 | 2024-11-01 | 真和制药有限公司 | 通过阻断tim-3和其配体的相互作用治疗癌症 |
| WO2020160156A2 (en) | 2019-01-30 | 2020-08-06 | Immutics, Inc. | Anti-gal3 antibodies and uses thereof |
| EP4157338A4 (en) | 2020-05-26 | 2024-11-13 | TrueBinding, Inc. | METHOD FOR TREATING INFLAMMATORY DISEASES BY GALECTIN-3 BLOCKING |
| US12365743B2 (en) | 2022-02-23 | 2025-07-22 | Xencor, Inc. | Anti-CD28 x anti-PSMA antibodies |
| WO2024040194A1 (en) | 2022-08-17 | 2024-02-22 | Capstan Therapeutics, Inc. | Conditioning for in vivo immune cell engineering |
| WO2024251884A1 (en) | 2023-06-09 | 2024-12-12 | Innate Pharma | Nk cell engager proteins comprising anti-cd20 and ant-nkp46 antibody, linked to il-2 in treatment of r/r b-nhl |
| US20250122299A1 (en) * | 2023-08-28 | 2025-04-17 | Xencor, Inc. | ANTI-CD20 x ANTI-CD28 COMBINATION THERAPIES |
| TW202602921A (zh) * | 2024-02-09 | 2026-01-16 | 大陸商上海岸邁生物科技有限公司 | 多功能ｎｋ細胞接合器 |
| WO2026055280A1 (en) * | 2024-09-04 | 2026-03-12 | Sanofi | Interleukin 2 (il-2) and cd123 nk cell engager combination therapy |
Family Cites Families (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5229109A (en) | 1992-04-14 | 1993-07-20 | Board Of Regents, The University Of Texas System | Low toxicity interleukin-2 analogues for use in immunotherapy |
| US6277375B1 (en) | 1997-03-03 | 2001-08-21 | Board Of Regents, The University Of Texas System | Immunoglobulin-like domains with increased half-lives |
| EP0979102A4 (en) | 1997-04-30 | 2005-11-23 | Enzon Inc | DETAILED POLYPEPTIDE MODIFIED BY POLYALKYLENE OXIDE |
| DK1071700T3 (da) | 1998-04-20 | 2010-06-07 | Glycart Biotechnology Ag | Glykosylerings-modifikation af antistoffer til forbedring af antistofafhængig cellulær cytotoksicitet |
| PL209392B1 (pl) | 1999-01-15 | 2011-08-31 | Genentech Inc | Przeciwciało, komórka gospodarza, sposób wytwarzania przeciwciała oraz zastosowanie przeciwciała |
| US7183387B1 (en) | 1999-01-15 | 2007-02-27 | Genentech, Inc. | Polypeptide variants with altered effector function |
| US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
| CA2704600C (en) | 1999-04-09 | 2016-10-25 | Kyowa Kirin Co., Ltd. | A method for producing antibodies with increased adcc activity |
| US20030133939A1 (en) | 2001-01-17 | 2003-07-17 | Genecraft, Inc. | Binding domain-immunoglobulin fusion proteins |
| CA2463879C (en) | 2001-10-25 | 2012-12-04 | Genentech, Inc. | Glycoprotein compositions |
| US20040132101A1 (en) | 2002-09-27 | 2004-07-08 | Xencor | Optimized Fc variants and methods for their generation |
| DK1534335T4 (en) | 2002-08-14 | 2015-10-05 | Macrogenics Inc | FCGAMMARIIB-SPECIFIC ANTIBODIES AND PROCEDURES FOR USE THEREOF |
| JP2004126818A (ja) | 2002-09-30 | 2004-04-22 | Toshiba Corp | 電子機器システム、電池ユニットおよび電池ユニットの動作制御方法 |
| CA2512729C (en) | 2003-01-09 | 2014-09-16 | Macrogenics, Inc. | Identification and engineering of antibodies with variant fc regions and methods of using same |
| US7960512B2 (en) | 2003-01-09 | 2011-06-14 | Macrogenics, Inc. | Identification and engineering of antibodies with variant Fc regions and methods of using same |
| WO2005040219A1 (en) | 2003-10-28 | 2005-05-06 | Novo Nordisk A/S | Laminin-5 gamma2-binding peptides, related compositions, and use thereof |
| WO2005047327A2 (en) | 2003-11-12 | 2005-05-26 | Biogen Idec Ma Inc. | NEONATAL Fc RECEPTOR (FcRn)-BINDING POLYPEPTIDE VARIANTS, DIMERIC Fc BINDING PROTEINS AND METHODS RELATED THERETO |
| JP5367982B2 (ja) | 2004-04-16 | 2013-12-11 | マクロジェニクス，インコーポレーテッド | ＦｃγＲＩＩＢ特異的抗体とその利用法 |
| CA2565874C (en) | 2004-05-10 | 2017-10-03 | Macrogenics, Inc. | Humanized fc.gamma.riib-specific antibodies and methods of use thereof |
| AU2005335714B2 (en) | 2004-11-10 | 2012-07-26 | Macrogenics, Inc. | Engineering Fc antibody regions to confer effector function |
| FR2879605B1 (fr) | 2004-12-16 | 2008-10-17 | Centre Nat Rech Scient Cnrse | Production de formats d'anticorps et applications immunologiques de ces formats |
| US20090208500A1 (en) | 2005-06-03 | 2009-08-20 | Genentech, Inc. | Method of producing antibodies with improved function |
| PL2573114T3 (pl) | 2005-08-10 | 2016-10-31 | Identyfikacja i inżynieria przeciwciał z wariantami regionów FC oraz sposoby ich stosowania | |
| EP1999470A4 (en) | 2006-03-10 | 2009-08-19 | Macrogenics Inc | IDENTIFICATION AND GENETIC MODIFICATION OF ANTIBODIES WITH HEAVY CHAINS OF VARIANTS AND METHODS OF USE THEREOF |
| WO2008105886A2 (en) | 2006-05-26 | 2008-09-04 | Macrogenics, Inc. | HUMANIZED FCγRIIB-SPECIFIC ANTIBODIES AND METHODS OF USE THEREOF |
| WO2008002933A2 (en) | 2006-06-26 | 2008-01-03 | Macrogenics, Inc. | Combination of fcgammariib antibodies and cd20-specific antibodies and methods of use thereof |
| JP6157046B2 (ja) | 2008-01-07 | 2017-07-05 | アムジェン インコーポレイテッド | 静電的ステアリング（ｅｌｅｃｔｒｏｓｔａｔｉｃｓｔｅｅｒｉｎｇ）効果を用いた抗体Ｆｃヘテロ二量体分子を作製するための方法 |
| MY192182A (en) | 2009-06-26 | 2022-08-04 | Regeneron Pharma | Readily isolated bispecific antibodies with native immunoglobulin format |
| EP2542256B1 (en) | 2010-03-04 | 2019-05-22 | MacroGenics, Inc. | Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof |
| EP2658869B1 (en) | 2010-12-30 | 2019-06-12 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Antigen binding formats for use in therapeutic treatments or diagnostic assays |
| SG192673A1 (en) | 2011-02-10 | 2013-09-30 | Roche Glycart Ag | Mutant interleukin-2 polypeptides |
| EA201892619A1 (ru) | 2011-04-29 | 2019-04-30 | Роше Гликарт Аг | Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2 |
| MX369148B (es) | 2012-09-19 | 2019-10-30 | Innate Pharma | Agentes de unión kir3dl2. |
| JP6822849B2 (ja) | 2014-06-27 | 2021-01-27 | イナート・ファルマ・ソシエテ・アノニムＩｎｎａｔｅ Ｐｈａｒｍａ Ｐｈａｒｍａ Ｓ．Ａ． | 多重特異的ＮＫｐ４６結合タンパク質 |
| AU2016284871B2 (en) * | 2015-06-23 | 2022-09-29 | Innate Pharma | Multispecific NK engager proteins |
| EP3397645B1 (en) | 2015-12-28 | 2026-03-25 | Innate Pharma | Variable regions for nkp46 binding proteins |
| WO2017165464A1 (en) * | 2016-03-21 | 2017-09-28 | Elstar Therapeutics, Inc. | Multispecific and multifunctional molecules and uses thereof |
| JP7325341B2 (ja) | 2017-07-11 | 2023-08-14 | シンソークス，インク． | 非天然ヌクレオチドの組み込み及びその方法 |
| KR20240141853A (ko) | 2017-08-03 | 2024-09-27 | 신톡스, 인크. | 자가면역 질환의 치료를 위한 사이토카인 접합체 |
| CA3098930A1 (en) | 2018-09-21 | 2020-03-26 | Innovent Biologics (Suzhou) Co., Ltd. | Novel interleukin-2 and use thereof |
| EP3980051A4 (en) | 2019-06-05 | 2023-09-13 | Asher Biotherapeutics, Inc. | FUSIONS OF MUTANT INTERLEUKIN-2 POLYPEPTIDES WITH ANTIGEN-BINDING MOLECULES TO MODULATE THE FUNCTION OF IMMUNE CELLS |
| WO2020252418A2 (en) | 2019-06-14 | 2020-12-17 | Cugene, Inc. | Novel interleukin-2 variants for the treatment of cancer |
-
2022
- 2022-06-08 KR KR1020237045295A patent/KR20240019786A/ko active Pending
- 2022-06-08 CN CN202280041605.8A patent/CN117529504A/zh active Pending
- 2022-06-08 WO PCT/EP2022/065514 patent/WO2022258673A1/en not_active Ceased
- 2022-06-08 AU AU2022288574A patent/AU2022288574A1/en active Pending
- 2022-06-08 US US18/568,806 patent/US20250002601A1/en active Pending
- 2022-06-08 IL IL308531A patent/IL308531A/en unknown
- 2022-06-08 JP JP2023575753A patent/JP2024521408A/ja active Pending
- 2022-06-08 BR BR112023025476A patent/BR112023025476A2/pt unknown
- 2022-06-08 MX MX2023014645A patent/MX2023014645A/es unknown
- 2022-06-08 CA CA3227227A patent/CA3227227A1/en active Pending
- 2022-06-08 EP EP22733563.5A patent/EP4351733A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024521408A5 (https=) | ||
| Labriola-Tompkins et al. | Identification of the discontinuous binding site in human interleukin 1 beta for the type I interleukin 1 receptor. | |
| Takatsu et al. | Interleukin 5, a T-cell-derived B-cell differentiation factor also induces cytotoxic T lymphocytes. | |
| Cherwinski et al. | Two types of mouse helper T cell clone. III. Further differences in lymphokine synthesis between Th1 and Th2 clones revealed by RNA hybridization, functionally monospecific bioassays, and monoclonal antibodies. | |
| US20210269502A1 (en) | Tumor-specific ifna secretion by car t-cells to reprogram the solid tumor microenvironment | |
| Naruse et al. | A YAC contig of the human CC chemokine genes clustered on chromosome 17q11. 2 | |
| Dumoutier et al. | IL-TIF/IL-22: genomic organization and mapping of the human and mouse genes | |
| Kobe et al. | The leucine-rich repeat: a versatile binding motif | |
| Wilson et al. | Clustering of cytokine genes on mouse chromosome 11. | |
| SE461223B (sv) | Mrna och cdna foer humant fibroblastinterferon, foerfarande foer deras framstaellning samt anvaendning daerav | |
| JPS63299A (ja) | ヒトｇ−ｃｓｆタンパク質の発現 | |
| SE465223B (sv) | Moget rekombinant-humanleukocytinterferon och foerfarande foer dess framstaellning | |
| US11542318B2 (en) | Use of chemokine receptor CXCR5 | |
| JPH03155795A (ja) | マウス・インターロイキン―６レセプター蛋白質 | |
| Chatchawan et al. | Oxynema, a new genus separated from the genus Phormidium (Cyanophyta) | |
| CN110615835A (zh) | 选择性地操纵靶细胞中对两个或更多个共有受体多肽识别的配体的细胞反应的方法 | |
| CN1193280A (zh) | 用于治疗的cd44基因表达的控制 | |
| CN114573709A (zh) | 携带趋化因子受体且靶向msln抗原的car t免疫细胞的制备及其用途 | |
| CN110684787B (zh) | 一种斑节对虾糖原合成酶激酶GSK3β基因及其应用 | |
| He et al. | Abundant members of Scavenger receptors family and their identification, characterization and expression against Vibrio alginolyticus infection in juvenile Larimichthys crocea | |
| Auron et al. | Multiple amino acid substitutions suggest a structural basis for the separation of biological activity and receptor binding in a mutant human interleukin-1. beta. protein | |
| CN1040822A (zh) | 胃动素样多肽的制备及表达 | |
| JP2024513231A5 (https=) | ||
| Marquardt et al. | The gene family coding for the light-harvesting polypeptides of Photosystem I of the red alga Galdieria sulphuraria | |
| JP2004533848A5 (https=) |